Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae b polysaccharide-tetanus conjugate
- Development stage
- Approved
- Lead developer
- Intravacc
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae b polysaccharide-tetanus conjugate is a vaccine used for active immunization to prevent invasive disease caused by Haemophilus influenzae type b (Hib) bacteria, particularly in children. The vaccine consists of purified capsular polysaccharide from Hib (polyribosyl-ribitol-phosphate, PRP) covalently bound to tetanus toxoid as a carrier protein. This conjugation converts the immune response from T-cell independent to T-cell dependent, resulting in robust antibody production and long-lasting immunity even in infants. The primary indication is the prevention of serious Hib infections such as meningitis, epiglottitis, pneumonia, pericarditis, and septic arthritis. It is administered intramuscularly and recommended for all children between 2 months and 5 years of age[1][2][3][4][5][8].
- Brand names
- HiberixActHIBHibtiterPedvaxhib
- Other names
- Haemophilus b conjugate vaccine (tetanus toxoid conjugate)Hib-TTPRP-T (polyribosyl-ribitol-phosphate–tetanus toxoid)
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on haemophilus influenzae b polysaccharide-tetanus conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae b polysaccharide-tetanus conjugate.